Halozyme

Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) were trading higher by 0.62 percent during Thursday's afternoon. Halozyme Therapeutics disclosed earlier in the day that AbbVie Inc (NYSE: ABBV) has dosed its first subject in a clinical trial evaluating the safety and pharmacokinetics of...